o a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10595278		
Filing Date		2006-04-04		
Art Unit		r PRUSAK 1714		
		1200318N US		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	5863964		1999-01-26	Teumac et al.	
	2	5874517		1999-02-23	Huang et al.	
	3	6569479		2003-05-07	Rule	
	4	6790499		2004-09-14	Andrews et al.	
	5	6911523		2005-06-28	Rule	
	6	6274212		2001-08-14	Rule et al.	
	7	6103774		2000-08-15	Rule	
	8	6492442		2002-12-10	Appel et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

6214929

Application Number		10595278
Filing Date		2006-04-04
First Named Inventor	Peter	PRUSAK
Art Unit		1714
Examiner Name K. A.		SANDERS
Attorney Docket Number		1200318N US

Pages,Columns,Lines where

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Name of Patentee or Applicant		Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	20030004244		2003-01-02		Al-Malaika		U.S. Published Application of V 00/66659 (published 2000-11-0			
	2	20040176539		2004-09-09		Odonsio et al.					
	3	20050176859		2005-08-11		Tinkl et al.				pplication of V shed 2003-04	
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIG	GN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i Code <sup>4</sup> Publication Name of Patentee or Applicant of cited Document Pages, Columers Releve Passages or Figures Appe				levant or Relevant	T4			
	1										
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	buttor	Add		
		_	NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (lock), magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5			
	1 Eastman Chemical, "Eastman Vitamin E TPGS for Clear Beverages" (1997)										

2001-04-10

If you wish to add additional U.S. Patent citation information please click the Add button.

Haremza et al.

U.S.PATENT APPLICATION PUBLICATIONS

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595278
Filing Date		2006-04-04
First Named Inventor Peter		PRUSAK
Art Unit		1714
Examiner Name K. A.		SANDERS
Attorney Docket Numb	er	1200318N US

	2	BASI	ASF "Uvrud Technical Information" (1999)				
	3	BASI	ASF "Uvruul 2000 AO Technical Information" (1999)				
	4	BASI	ASF "Uvrnul 2003 AO Technical Information" (1999)				
If you wis	h to a	dd add	dditional non-patent literature document citation information please click the Add but	ton Add			
EXAMINER SIGNATURE							
Examiner	Examiner Signature Date Considered						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a							

See Kint Codes of USPTO Patent Documents at year USPTO\_CODV or NPEP 901.6. <sup>2</sup> Extent office that issued the document, by the holietier code (WIPO Standard ST.3). <sup>2</sup> Strong Jungsness patent countered, by enabling of the Parent of the Emperor must procedule be serial number of the plant of countered, be not countered, be not countered, by the proprieties symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>3</sup> Applicant is to place a check mark here it English targuages the resistance is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595278
Filing Date		2006-04-04
First Named Inventor Peter		PRUSAK
Art Unit		1714
Examiner Name	K.A.	SANDERS
Attorney Docket Numb	er	1200318N US

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate selection(s):
---------------	----------	------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sidelosure statement. See 37 CFR 137(a)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/John H. Homickel/	Date (YYYY-MM-DD)	2006-10-03
Name/Print	John H. Homickel	Registration Number	29393

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.